Technology
Share your love
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
AOAExcel Endorses Barti Software as First Eye Care EHR
AOAExcel, a for-profit subsidiary and member-benefit arm of the American Optometric Association (AOA), has announced its first-ever endorsement of an Electronic Health Records (EHR) system—Barti Software. This partnership includes a financial investment in the San Francisco-based EHR provider, marking a…
NHS Launches OCT Scans for Diabetic Eye Care
The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…
USC Receives $6M Grant for Dry AMD Therapy
The California Institute for Regenerative Medicine (CIRM) has awarded a $6 million, two-year grant to researchers at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute. This funding will advance preclinical studies…
EO2002: Non-Surgical Solution for Corneal Edema
Emmecell has announced positive results from its U.S. multicenter Phase 1 trial evaluating EO2002, an innovative non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in best corrected visual acuity (BCVA) and reductions in central corneal…
Positive Phase 3 Results for MELT-300 Sedation
Melt Pharmaceuticals has reported promising topline results from the pivotal Phase 3 trial of MELT-300, a novel, non-intravenous, non-opioid sedation tablet developed for use during cataract surgeries. The study, conducted under an FDA-approved Special Protocol Assessment (SPA) agreement, demonstrated that…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…
AbbVie Introduces Refresh Tears PF and Refresh Relieva PF Xtra
AbbVie has introduced two new preservative-free (PF) lubricant eye drop products─Refresh Tears PF and Refresh Relieva PF Xtra. These new additions aim to enhance the options available for eye care with innovative features tailored for user convenience and eye health.…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…